Reducing Recurrent Urinary Tract Infections in Women with MV140 Impacts Personal Burden of Disease: Secondary Analyses of a Randomized Placebo-controlled Efficacy Study.
| Autor: | Curtis Nickel J; Queen's University, Kingston, ON, Canada., Foley S; Royal Berkshire Hospital, Reading, UK., Yang B; Royal Berkshire Hospital, Reading, UK., Casanovas M; Inmunotek S.L., Alcalá de Henares, Madrid, Spain., Caballero R; Inmunotek S.L., Alcalá de Henares, Madrid, Spain., Diez-Rivero CM; Inmunotek S.L., Alcalá de Henares, Madrid, Spain., Lorenzo-Gómez MF; University Hospital of Salamanca, Salamanca, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European urology open science [Eur Urol Open Sci] 2024 Mar 29; Vol. 63, pp. 96-103. Date of Electronic Publication: 2024 Mar 29 (Print Publication: 2024). |
| DOI: | 10.1016/j.euros.2024.03.010 |
| Abstrakt: | Background: Recurrent urinary tract infection (rUTI) remains a major health burden for women. A randomized, double-blind, placebo-controlled trial (RCT; NCT02543827) reported that female patients with rUTI receiving a sublingual vaccine, MV140, had a reduction in rUTI and increase in UTI-free rate compared with placebo. Objective: To determine the impact of MV140 on the personal burden of disease in women with rUTI using secondary endpoint data from the pivotal RCT evaluating MV140. Design Setting and Participants: In the primary RCT, female patients with rUTI enrolled in Spain and UK (from October 2015 to April 2019) were randomized to placebo (6 mo) or MV140 (3 or 6 mo), and followed for 12 mo. Individuals analyzed in this secondary analysis included those in the placebo and 3-mo (recommended dose) groups. Intervention: A polybacterial sublingual vaccine, MV140 (four inactivated whole-cell bacteria- Escherichia coli , Klebsiella pneumoniae , Proteus vulgaris , and Enterococcus faecalis ), or placebo. Outcome Measurements and Statistical Analysis: Symptom severity scoring, antibiotic use, safety, and multiple aspects of quality of life (QoL; Short-Form Questionnaire [SF-36]) were assessed. Results and Limitations: Compared with the placebo group ( n = 76), the 3-mo vaccinated group ( n = 74) experienced fewer overall UTI symptoms (mean symptom score 102.2 ± 222.9 vs 194.2 ± 178.8; p = 0.0002), fewer days on antibiotics (12.4 ± 17.7 vs 28.7 ± 25.2; p = 0.0001), and improved total, general, and physical SF-36 QoL improvement (differences in means for total SF-36 score 15.7; 95% confidence interval [CI] 8.80, 22.64; p < 0.0001), with only social function QoL showing no impact (4.07; 95% CI -4.93, 13.08; p = 0.3744). Conclusions: Three months of MV140 is associated with a reduction of the personal burden of UTI by reducing overall UTI symptoms and antibiotic use, improving QoL in women with rUTI. Patient Summary: Three months of MV140 vaccine, which has previously been shown to reduce the risk of urinary tract infection safely, is associated with a reduction in the personal burden of disease. (© 2024 The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|